Search results
8 maj 2018 · PSA-based screening for prostate cancer has both potential benefits and harms. The USPSTF does not recommend screening for prostate cancer unless men express a preference for screening after being informed of and understanding the benefits and risks.
- Screening for Prostate Cancer - United States Preventive Services Task ...
The Task Force reviewed research studies on the...
- Screening for Prostate Cancer: USPSTF Recommendation Statement
Methods: The USPSTF reviewed new evidence on the benefits...
- Screening for Prostate Cancer - United States Preventive Services Task ...
The Task Force reviewed research studies on the prostate-specific antigen (PSA) screening test for prostate cancer. It concluded that the expected harms of PSA screening are greater than the potential benefit. This fact sheet explains the Task Force recommendation and what it might mean for you.
Methods: The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)–based screening for pros-tate cancer, as well as the benefits and harms of treatment of localized prostate cancer. Recommendation: The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).
8 maj 2018 · Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer.
The USPSTF grade C recommendation for prostate cancer screening 3 has restarted a national discussion on prostate cancer early detection. The Task Force deserves credit for this more balanced, fairer approach.
Guidelines on prostate cancer screening from the U.S. Preventive Services Task Force (USPSTF)—including draft updates released in 2017—apply to adult men who have not been previously diagnosed with prostate cancer
This report examines prostate cancer screening in the context of general costs of care concerns, the legal basis for coverage of preventive services without patient cost-sharing, whether prostate cancer screening has been shown to meet the criteria for benefits provided without patient cost-sharing, key clinical practice guidelines for prostate ...
